Total Payments
$15,695
2024 Payments
$571.26
Companies
41
Transactions
473
Medicare Patients
3,552
Medicare Billing
$246,359
Payment Breakdown by Category
Food & Beverage$11,803 (75.2%)
Travel$3,864 (24.6%)
Education$28.32 (0.2%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $11,803 | 454 | 75.2% |
| Travel and Lodging | $3,864 | 15 | 24.6% |
| Education | $28.32 | 4 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Abbott Laboratories | $4,924 | 54 | $0 (2024) |
| Medtronic Vascular, Inc. | $1,880 | 22 | $0 (2020) |
| Amgen Inc. | $841.10 | 56 | $0 (2023) |
| ABIOMED | $762.95 | 24 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $718.36 | 50 | $0 (2024) |
| PFIZER INC. | $712.67 | 44 | $0 (2024) |
| Impulse Dynamics (USA) Inc. | $700.96 | 10 | $0 (2024) |
| Boston Scientific Corporation | $662.68 | 11 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $428.23 | 22 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $411.83 | 20 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $571.26 | 28 | Impulse Dynamics (USA) Inc. ($83.06) |
| 2023 | $2,090 | 97 | Impulse Dynamics (USA) Inc. ($490.24) |
| 2022 | $2,117 | 107 | Abbott Laboratories ($299.90) |
| 2021 | $36.00 | 1 | Abbott Laboratories ($36.00) |
| 2020 | $1,107 | 51 | Amgen Inc. ($235.52) |
| 2019 | $6,504 | 136 | Abbott Laboratories ($4,072) |
| 2018 | $808.38 | 26 | Abbott Laboratories ($143.80) |
| 2017 | $2,461 | 27 | Medtronic Vascular, Inc. ($1,690) |
All Payment Transactions
473 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $19.03 | General |
| Category: Cardiology | ||||||
| 10/21/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $14.70 | General |
| Category: Cardiology | ||||||
| 08/16/2024 | Medtronic, Inc. | COBALT DR MRI SURESCAN (Device) | Food and Beverage | In-kind items and services | $13.32 | General |
| Category: Implantable Cardioverter Defibrillators (ICDs) | ||||||
| 08/10/2024 | Medtronic, Inc. | COBALT DR MRI SURESCAN (Device) | Food and Beverage | In-kind items and services | $23.01 | General |
| Category: Implantable Cardioverter Defibrillators (ICDs) | ||||||
| 06/19/2024 | Impulse Dynamics (USA) Inc. | Optimizer (Device), Optimizer | Food and Beverage | Cash or cash equivalent | $43.11 | General |
| Category: Cardiovascular Device | ||||||
| 04/30/2024 | Alnylam Pharmaceuticals Inc. | ONPATTRO (Drug) | Food and Beverage | In-kind items and services | $15.17 | General |
| Category: Genetic Disease | ||||||
| 04/11/2024 | Abbott Laboratories | GALLANT (Device) | Food and Beverage | In-kind items and services | $17.00 | General |
| Category: Cardiac Rhythm Management | ||||||
| 03/14/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $15.32 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 03/12/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $21.41 | General |
| Category: CARDIOVASCULAR | ||||||
| 03/07/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $14.72 | General |
| Category: Cardiovascular | ||||||
| 02/15/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $13.77 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 02/13/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $15.95 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 02/08/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $15.14 | General |
| Category: Cardiovascular | ||||||
| 02/06/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $18.23 | General |
| Category: Not Applicable | ||||||
| 02/02/2024 | Impulse Dynamics (USA) Inc. | Optimizer (Device), Optimizer | Food and Beverage | Cash or cash equivalent | $39.95 | General |
| Category: Cardiovascular Device | ||||||
| 02/02/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $17.91 | General |
| Category: DIABETES | ||||||
| 02/01/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Food and Beverage | In-kind items and services | $17.09 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 02/01/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $16.81 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 01/30/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $17.78 | General |
| Category: Cardio-renal | ||||||
| 01/26/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $19.07 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 01/19/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $14.78 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 01/15/2024 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID, NURTEC ODT | Food and Beverage | In-kind items and services | $20.41 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 01/12/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $30.03 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 01/10/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $16.75 | General |
| Category: Not Applicable | ||||||
| 01/09/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $16.60 | General |
| Category: Cardiovascular | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 25 | 1,637 | 1,923 | $424,159 | $98,710 |
| 2022 | 19 | 1,008 | 1,176 | $277,765 | $74,305 |
| 2020 | 21 | 907 | 1,171 | $201,111 | $73,345 |
Total Patients
3,552
Total Services
4,270
Medicare Billing
$246,359
Procedure Codes
67
All Medicare Procedures & Services
67 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 73 | 73 | $51,193 | $23,826 | 46.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 205 | 227 | $54,625 | $19,342 | 35.4% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 123 | 124 | $81,904 | $16,515 | 20.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 44 | 44 | $13,703 | $5,203 | 38.0% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 93 | 95 | $33,818 | $4,650 | 13.8% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 423 | 451 | $69,567 | $4,478 | 6.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 63 | 63 | $10,560 | $3,591 | 34.0% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 16 | 64 | $4,716 | $2,749 | 58.3% |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | Office | 2023 | 28 | 56 | $18,889 | $2,725 | 14.4% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 259 | 338 | $11,661 | $1,988 | 17.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 21 | 21 | $4,494 | $1,751 | 39.0% |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | Office | 2023 | 11 | 11 | $2,201 | $1,751 | 79.6% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 25 | 35 | $8,398 | $1,684 | 20.0% |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | Office | 2023 | 16 | 16 | $7,570 | $1,536 | 20.3% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 30 | 30 | $5,382 | $1,438 | 26.7% |
| Q9957 | Injection, perflutren lipid microspheres, per ml | Office | 2023 | 24 | 41 | $7,899 | $1,319 | 16.7% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 22 | 23 | $2,176 | $884.58 | 40.7% |
| 93295 | Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | Office | 2023 | 18 | 27 | $8,391 | $540.55 | 6.4% |
| 93298 | Evaluation of cardiac rhythm monitor system, remote up to 30 days | Office | 2023 | 11 | 32 | $2,886 | $525.62 | 18.2% |
| 93296 | Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | Office | 2023 | 33 | 43 | $8,165 | $513.90 | 6.3% |
| 93290 | Evaluation of implantable heart and blood vessel monitoring system | Office | 2023 | 13 | 15 | $2,504 | $378.14 | 15.1% |
| 93297 | Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | Office | 2023 | 17 | 24 | $1,594 | $358.92 | 22.5% |
| 93227 | Electrocardiogram (ecg) 2-day continuous with review by health care professional | Office | 2023 | 21 | 21 | $3,155 | $271.70 | 8.6% |
| 93225 | Electrocardiogram (ecg) 2-day continuous | Office | 2023 | 21 | 21 | $4,759 | $256.61 | 5.4% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 15 | 16 | $1,823 | $254.43 | 14.0% |
About Dr. John Nayda, M.D
Dr. John Nayda, M.D is a Cardiovascular Disease healthcare provider based in Rochester, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/29/2011. The National Provider Identifier (NPI) number assigned to this provider is 1952690026.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Nayda, M.D has received a total of $15,695 in payments from pharmaceutical and medical device companies, with $571.26 received in 2024. These payments were reported across 473 transactions from 41 companies. The most common payment nature is "Food and Beverage" ($11,803).
As a Medicare-enrolled provider, Nayda has provided services to 3,552 Medicare beneficiaries, totaling 4,270 services with total Medicare billing of $246,359. Data is available for 3 years (2020–2023), covering 67 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Rochester, NY
- Active Since 03/29/2011
- Last Updated 02/20/2018
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1952690026
Products in Payments
- Mitra Clip system (Device) $1,916
- Resolute (Device) $1,690
- Xience V coronary stent system (Device) $1,651
- Repatha (Biological) $816.65
- Impella (Device) $762.95
- ELIQUIS (Drug) $756.38
- ENTRESTO (Drug) $579.01
- OPTIMIZER (Device) $490.24
- Quadra Assura CRT Defibrillator (Device) $407.15
- JARDIANCE (Drug) $402.57
- XARELTO (Drug) $372.53
- RESONATE (Device) $363.09
- VERQUVO (Drug) $306.60
- Edwards SAPIEN 3 Transcatheter Heart Valve (Device) $284.00
- Omnilink Elite vascular stent system (Device) $281.45
- FARXIGA (Drug) $222.19
- Optimizer (Device) $210.72
- Fortify Assura, Ellipse ICD (Device) $197.91
- QUADRA ASSURA (Device) $187.88
- WATCHMAN (Device) $186.72
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Rochester
Samuel Asirvatham, M.d, M.D
Cardiovascular Disease — Payments: $1.5M
Cardiovascular Disease $1.5M
Srijoy Mahapatra, M.d, M.D
Cardiovascular Disease — Payments: $1.2M
Cardiovascular Disease $1.2M
Amir Lerman, M.d, M.D
Cardiovascular Disease — Payments: $590,259
Cardiovascular Disease $590,259
Charanjit Rihal, M.d, M.D
Cardiovascular Disease — Payments: $484,688
Cardiovascular Disease $484,688
Martha Grogan, M.d, M.D
Cardiovascular Disease — Payments: $402,326
Cardiovascular Disease $402,326
David Hayes, M.d, M.D
Cardiovascular Disease — Payments: $278,959
Cardiovascular Disease $278,959